MRD negative complete remissions following anti-CD22 CAR in relapsed/refractory ALL

Press brief presented by Terry J. Fry, MD of Center for Cancer Research, Bethesda, MD, on MRD negative complete remissions following anti-CD22 CAR in children and young adults with relapsed/refractory ALL. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Share this video  
Similar topics
3rd December 2016